Volume 7, Issue 1 (Jan-Mar 2002)

Molecular mechanisms underlying a closely related triplet: anemia, tumor hypoxia and radiotherapy – EDITORIAL (pages 7 to 8)

N. Ziras (Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece)

Lesson on Leukemia (pages 9 to 11)

E. J. Freireich (The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA)

The role of CA 125 in epithelial ovarian carcinoma (pages 13 to 17)

H. Mandeville (Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK), G. J.S. Rustin

Tumor angiogenesis in gynecological oncology (pages 19 to 23)

A. Mandi (Department of Gynecologic Oncology, Institute of Oncology Sremska Kamenica, Novi Sad, Yugoslavia), T. Vujkov, P. Novakovi, S. Komazec

Syndrome after pneumonectomy (pages 25 to 30)

N. Baltayiannis (Department of Thoracic Surgery, Metaxa Cancer Hospital, Piraeus, Greece), N. Bolanos

The impact of the haemoglobin level on the response to radiotherapy (pages 31 to 34)

A. Haydarolu (Ege University Faculty of Medicine, Department of Radiation Oncology, Izmir, Turkey), V. Yrt, A. Arican, D. Yalman, A. Blent Aras, M. Esassolak, S. zkk

Methotrexate, etoposide, ifosfamide and cisplatin (MVIP) an effective first-line therapy for IGCCC intermediate poor prognosis patients with germ-cell tumors. Single institution experience (pages 35 to 41)

A. E. Athanassiou (Department of Medical Oncology A, Metaxa Cancer Hospital, Piraeus, Greece), A. Potamianou, N. Bountouroglou, N. Ziras, A. Frangoulidis, J. Varthalitis, N. Karvounis, C. Chrysanthou, D. Pectasidis

First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study (pages 43 to 46)

T. E. Ciuleanu (University of Medicine and Pharmacy I. Hatieganu Cluj-Napoca, Romania), R. Curc, D. Iancu, N. Todor, C. Cebotaru, I. Radulescu, E. Banu, N. Ghilezan

Combined chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer (pages 47 to 51)

S. Isakovi-Vidovi (Department of Radiotherapy, Institute of Oncology and Radiology of Serbia, Beograd, Yugoslavia), L. Radosevi-Jeli, N. Borojevi

Selective neck dissection for cervical node negative supraglottic carcinoma (pages 53 to 56)

Petrovi (Institute of Otorhinolaryngology and Maxillofacial Surgery, Clinical Center of Serbia, Beograd, Yugoslavia)

Control of acute emesis in repeated courses of moderately emetogenic chemotherapy (pages 57 to 60)

J. Raynov (Department of Haematology Oncology, Military Medical Academy, Sofia, Bulgaria), S. Danon, Z. Valerianova

Familial breast cancer. Part II Relationships with histology, staging, steroid receptors and serum tumor markers (pages 61 to 65)

I. Gavrilov (Department of Thoracic Surgery, National Oncological Centre, Sofia, Bulgaria), M. Nacheva, D. Tzingilev

Benign and malignant struma ovarii report of three cases and review of the literature (pages 67 to 70)

A. Mandi (Department of Gynaecologic Oncology, Institute of Oncology Sremska Kamenica, Novi Sad, Yugoslavia), J. Rajovi, M. Tesi, T. Vujkov, D. Krnojelac, S. Komazec

Primary osteosarcoma of the sphenoid bone with multiple recurrences a case report and review of the literature (pages 71 to 74)

Z. zsaran (Department of Radiation Oncology, Ege University Medical School, Izmir, Turkey), Y. Anacak, M. Esassolak, E. Goker, D. Yalman, A. Haydaroglu, F. Oztop

Small cell carcinoma of the rectum report of a case (pages 75 to 77)

F. Tokatli (Department of Radiation Oncology, Faculty of Medicine, Trakya University,Edirne, Turkey), Z. Koak, F. zyilmaz, K. Uygun, M. aloglu, C. Uzal

Renal tumours historical notes (pages 79 to 84)

G. Androutsos (History of Medicine, Faculty of Medicine, University of Ioannina, Ioannina, Greece)

Combined modality treatment for stage III non-small cell lung cancer: the performance, the actors and the backstage – LETTER TO THE EDITOR (pages 85 to 86)

M. Dediu (Department of Medical Oncology, Institute of Oncology Bucharest, Bucharest, Romania), N. Ziras

Reset link sent!

Link for password reset has been emailed to you. Please check your email.